



Nevada Provider News

October 2019 Anthem Provider News and Important Updates

- Nevada

Pharmacy:

Anthem specialty pharmacy medical step therapy drug list- clarification	3
Important update to Anthem's commercial drug lists	4
Pharmacy information available on anthem.com	32

Administrative:

Anthem launches additional changes to anthem.com	5
Drug fee schedule update	8
National Accounts 2020 Pre-certification list	8
Anthem Commercial Risk Adjustment (CRA) Reporting Update: Retrospective Program continues	8
Anthem engages Matrix to conduct mobile health clinics and in-home assessments for targeted members	9

Reimbursement Policies:

Place of Service (Professional Reimbursement Policy - Update) (MAC)	11
---	----

Federal Employee Plan (FEP):

Federal Employee Program® Specialty Pharmacy Clinical Site of Care prior authorization review (MAC)	11
Pre-certification request turnaround times for the Federal Employee Program	11
US Antibiotic Awareness Week is November 11-18, 2019	12

Medicare:

Medical Policies and Clinical Utilization Management Guidelines update	13
Update: 2019 risk adjustment provider trainings	19
Medicare preferred continuous glucose monitors	21

Medical drug Clinical Criteria updates	22
Prior authorization requirements changes effective November 1, 2019	22
MCG Care Guidelines update and customizations	26
Keep up with Medicare news	27
 Medicaid:	
New pregnancy notification process using the Availity Portal	27
Benefit Look-Up Tool	
Prior authorization changes	28
Prior authorization requirements for hyperbaric oxygen and supervision of hyperbaric oxygen therapy	30
MCG Care Guidelines update and customizations	31
Keep up with Medicaid news	32

Anthem Blue Cross and Blue Shield is the trade name of: In Colorado Rocky Mountain Hospital and Medical Service, Inc. HMO products underwritten by HMO Colorado, Inc. In Connecticut: Anthem Health Plans, Inc. In Georgia: Blue Cross Blue Shield Healthcare Plan of Georgia, Inc. In Indiana: Anthem Insurance Companies, Inc. In Kentucky: Anthem Health Plans of Kentucky, Inc. In Maine: Anthem Health Plans of Maine, Inc. In Missouri (excluding 30 counties in the Kansas City area): RightCHOICE® Managed Care, Inc. (RIT), Healthy Alliance® Life Insurance Company (HALIC), and HMO Missouri, Inc. RIT and certain affiliates administer non-HMO benefits underwritten by HALIC and HMO benefits underwritten by HMO Missouri, Inc. RIT and certain affiliates only provide administrative services for self-funded plans and do not underwrite benefits. In Nevada: Rocky Mountain Hospital and Medical Service, Inc. HMO products underwritten by HMO Colorado, Inc. dba HMO Nevada. In New Hampshire: Anthem Health Plans of New Hampshire, Inc. HMO plans are administered by Anthem Health Plans of New Hampshire, Inc. and underwritten by Matthew Thornton Health Plan, Inc. In Ohio: Community Insurance Company. In Virginia: Anthem Health Plans of Virginia, Inc. trades as Anthem Blue Cross and Blue Shield in Virginia, and its service area is all of Virginia except for the City of Fairfax, the Town of Vienna, and the area east of State Route 123. In Wisconsin: Blue Cross Blue Shield of Wisconsin (BCBSWI), which underwrites or administers the PPO and indemnity policies and underwrites the out of network benefits in POS policies offered by CompCare or WCIC; CompCare Health Services Insurance Corporation (CompCare) underwrites or administers the HMO policies and Wisconsin Collaborative Insurance Company (WCIC) underwrites or administers Well Priority HMO or POS policies. Independent licensees of the Blue Cross and Blue Shield Association. Anthem is a registered trademark of Anthem Insurance Companies, Inc. The Blue Cross and Blue Shield names and symbols are registered marks of the Blue Cross and Blue Shield Association. Use of the Anthem websites constitutes your agreement with our Terms of Use.

Anthem specialty pharmacy medical step therapy drug list-clarification

Published: Oct 1, 2019 - Products & Programs / Pharmacy

In the February and May editions of *Provider News*, we shared that the following clinical criteria will be effective May 1, 2019 for the non-oncology uses of these drugs. We will now also begin the medical step therapy review process for **oncology** uses of these drugs starting October 1, 2019.

Colony Stimulating Factor Agents ING-CC-0002

Effective for dates of service on and after May 1, 2019, the following specialty pharmacy codes from new or current criteria will be included in our existing specialty pharmacy medical step therapy review process. Zarxio® will be the preferred short-acting colony stimulating factor (CSF) agent over Neupogen®, Granix®, and Nivestym™®.

Anthem Blue Cross and Blue Shield (Anthem)'s prior authorization clinical review of these specialty pharmacy drugs will be managed by AIM Specialty Health® (AIM), a separate company.

Additional information regarding biosimilar drugs can be found by viewing the reference document, [Biosimilar Drugs – What are they?](#)

To access the clinical criteria information please click [here](#).

Clinical Criteria	Status	Drug	HCPCS or CPT Code	NDC Code
ING-CC-0002	Preferred Agent	Zarxio®	Q5101	61314-0304-01 61314-0304-10 61314-0312-01 61314-0312-10 61314-0318-01 61314-0318-10 61314-0326-01 61314-0326-10
ING-CC-0002	Non-Preferred Agent	Neupogen®	J1442	55513-0530-01 55513-0530-10

55513-0546-01
 55513-0546-10
 55513-0924-01
 55513-0924-10
 55513-0924-91
 55513-0209-01
 55513-0209-10
 55513-0209-91

ING-CC-0002	Non-Preferred Agent	Granix®	J1447	63459-0910-11 63459-0910-12 63459-0910-15 63459-0910-17 63459-0910-36 63459-0912-11 63459-0912-12 63459-0912-15 63459-0912-17 63459-0912-36
ING-CC-0002	Non-Preferred Agent	Nivestym™	Q5110	00069-0291-10 00069-0291-01 00069-0292-01 00069-0292-10

URL: <https://providernews.anthem.com/nevada/article/anthem-specialty-pharmacy-medical-step-therapy-drug-list-clarification-2>

Important update to Anthem’s commercial drug lists

Published: Oct 1, 2019 - **Products & Programs** / Pharmacy

Effective with dates of service on and after October 1, 2019, and in accordance with Anthem Blue Cross and Blue Shield (Anthem)’s Pharmacy and Therapeutic (P&T) process, Anthem will update its commercial drug lists. Updates may include changes to drug tiers or the removal of a drug.

To help ensure a smooth transition and minimize member costs, providers should review these changes and consider prescribing a preferred drug to patients currently using a non-preferred drug, if appropriate.

Please note, this update does not apply to the Select Drug List or drugs lists utilized by the Federal Employee Program (FEP).

To view a summary of changes, select [here](#).

URL: <https://providernews.anthem.com/nevada/article/important-update-to-anthems-commercial-drug-lists-7>

Anthem launches additional changes to anthem.com

Published: Oct 1, 2019 - **Administrative**

Exciting new changes are on the horizon for the public provider site at anthem.com. These next wave of updates include:

- A new Contact Us page that gives providers easy access to important contact information
- A redesigned Medicare Advantage page with an improved, effortless user experience
- Clear and easy access to training and education materials through a new Training and Education page
- A new Enhanced Personal Health Care (EPHC) page that provides a more prominent and easier access to information that communicates Anthem's role in transforming health care. (EPHC is a program designed to advance and support a patient-centered approach to care delivery.)

Below is a preview of the new Contact Us and Medicare Advantage page:



Contact Us

Looking for help? Need to mail us a form? The resources below will direct you to the right place. For eligibility-related questions, call the number of the back of the member's ID card or dial (800) 676-BLUE (2583).

[Escalation Contact List](#)

[Prefix Reference List](#)

Additional Support

Get the support you need so you can focus on providing patient care. Below you will find contact information for our most commonly accessed services. For assistance with Anthem.com website issues, please call us at (866) 755-2680.



Avelity Support

For questions related to Avelity, contact the Avelity support team at (800) 282-4548 or submit a ticket online.

[Go to Avelity >](#)



EDI Support

You can contact the Electronic Data Interchange help desk at (800) 470-9630 or send an email for assistance.

[Email EDI Support >](#)



AIM Support

Get convenient online service through ProviderPortal, or call AIM Specialty Health for support at (800) 554-0580.

[Access ProviderPortal >](#)

Provider Maintenance Form

Use the Provider Maintenance Form to submit changes or additions to your information. If you are unsure which form to complete, please reach out to your Provider Contract Specialist for assistance.

[View the Provider Maintenance Form >](#)

Information for

Change State



Medicare Advantage Providers

<Brand> offers a variety of Medicare plans to support member needs. We also support our providers through access to information about our plans and member benefits, news and updates, training materials and guides, and other helpful resources.

Plans & Benefits

Below you will find evidence of coverage (EOC) and summary of benefits (SOB) documents for our Individual [Medicare Advantage products](#). If the product you are searching for is not in the lists below, please call the number on the back of the member's ID card.

2019

2018

Anthem MediBlue Plus (HMO)



URL: <https://providernews.anthem.com/nevada/article/anthem-launches-additional-changes-to-anthemcom-3>

Drug fee schedule update

Published: Oct 1, 2019 - **Administrative**

CMS average sales price (ASP) fourth quarter fee schedule with an effective date of October 1, 2019 will go into effect with Anthem Blue Cross and Blue Shield (Anthem) on November 1, 2019. To view the ASP fee schedule, please visit the CMS website at <http://www.cms.hhs.gov/McrPartBDrugAvgSalesPrice/>.

URL: <https://providernews.anthem.com/nevada/article/drug-fee-schedule-update-4>

National Accounts 2020 Pre-certification list

Published: Oct 1, 2019 - **Administrative**

The [National Accounts 2020 Pre-certification list](#) has been published. Please note, providers should continue to verify member eligibility and benefits prior to rendering services.

URL: <https://providernews.anthem.com/nevada/article/national-accounts-2020-pre-certification-list-3>

Anthem Commercial Risk Adjustment (CRA) Reporting Update: Retrospective Program continues

Published: Oct 1, 2019 - **Administrative**

Continuing our 2019 CRA updates, Anthem requests your assistance with respect to accurately reporting our member's health status to CMS.

2019 Retrospective Chart Request

Retrospective medical chart collection begins in November and it is the most significant and largest volume of our requests. We appreciate your collaboration as we work through the requests and submit to your medical records department in a timely manner.

Electronic options for chart collections

We have 4 electronic options for chart collections to choose from:

Remote/Direct Anthem Access

Electronic Medical Record (EMR) Interoperability with 4 EMR systems

Inovalon virtual visit or onsite

Secure FTP

Submitting medical charts can be time consuming for your staff. Utilizing an electronic option can alleviate the constraints on your staff's resources and time.

The most efficient electronic option is to allow the Anthem medical coder team to have direct connection access to your EMR system (Option 1), so that we may retrieve the records ourselves. Our team has collaborated with several Providers and Facilities to have direct access to their EMR systems to collect the charts. This allows for no vendor interventions and fewer handoffs of the records. *To address compliance concerns, please note that as a health plan, Anthem is a covered entity under the HIPAA Privacy Rule and is bound to protect PHI.*

If you are interested in any of these electronic options, or you would like to grant Anthem medical coders direct access to your EMR system, please contact Socorro.Carrasco@anthem.com, our Commercial Risk Adjustment Representative who supports your area.

Thank you for your continued efforts with our CRA Program, and your help in expediting chart collection requests.

URL: <https://providernews.anthem.com/nevada/article/anthem-commercial-risk-adjustment-cra-reporting-update-retrospective-program-continues-1>

Anthem engages Matrix to conduct mobile health clinics and in-home assessments for targeted members

Published: Oct 1, 2019 - **Administrative**

Matrix Mobile Bus

As we continue our efforts to help ensure our members enrolled in Affordable Care Act (ACA) compliant plans have their chronic conditions assessed and documented each year, Anthem Blue Cross and Blue Shield (Anthem) is engaging Matrix to help encourage members – on our behalf – to schedule a mobile health clinic assessment. A vendor, Matrix

operates the largest fleet of mobile medical centers nationwide and has conducted more than 1,000,000 patient assessments since 1998 – providing convenient access to comprehensive health assessments.

The mobile clinic provides members with additional options to help them close any gaps in care that they may have. In late July, Matrix began reaching out to members on our behalf by letter and phone. Our outreach efforts will continue until the end of this year.

Matrix works with hospitals and health plans like Anthem to deliver preventive health testing to the communities Matrix serves. Each mobile clinic has a reception area and private screening rooms. Matrix also helps members with scheduling follow-up appointments with their PCPs at the end of the assessments and forwards the PCPs a copy of any results from the health assessment.

Matrix In-Home Assessments

Matrix will perform in-home assessments where possible. The in-home assessments offer a board-certified nurse practitioner (NP) to come to a member's home to provide a general exam, suggestions for important screenings or other tests, a full review of the medicines they take, answers to health-related questions and a personal health summary detailing their health information. A copy of the assessment will be sent to members' PCPs to ensure continuity of care.

The overall goals of the mobile clinic program and the in-home program are to provide convenient, comprehensive appointments that are designed to complement the care provided by our network of physicians. **These mobile clinic or in-home visits do not replace any active treatment plans members currently have with their physicians and are not considered wellness visits or a substitute for members' annual physical examinations.**

We're including information about the program in this edition of *Provider News* should patients contact you about the program. Please refer members directly to Matrix if they have questions or need more information:

- **Mobile Bus: 888-822-3247**
- **In-Home: 855-403-0967**

URL: <https://providernews.anthem.com/nevada/article/anthem-engages-matrix-to-conduct-mobile-health-clinics-and-in-home-assessments-for-targeted-members-3>

Place of Service (Professional Reimbursement Policy - Update) (MAC)

Published: Oct 1, 2019 - **Policy Updates** / Reimbursement Policies

Material Adverse Change (MAC)

[Place of Service \(Professional Reimbursement Policy - Update\)](#)

URL: <https://providernews.anthem.com/nevada/article/place-of-service-professional-reimbursement-policy-update-mac-1>

Federal Employee Program® Specialty Pharmacy Clinical Site of Care prior authorization review (MAC)

Published: Oct 1, 2019 - **State & Federal** / Federal Employee Plan (FEP)

Material Adverse Change (MAC)

[Federal Employee Program® Specialty Pharmacy Clinical Site of Care prior authorization review](#)

URL: <https://providernews.anthem.com/nevada/article/federal-employee-program-specialty-pharmacy-clinical-site-of-care-prior-authorization-review-mac-1>

Pre-certification request turnaround times for the Federal Employee Program

Published: Oct 1, 2019 - **State & Federal** / Federal Employee Plan (FEP)

The Anthem Blue Cross Blue Shield Service Benefit Plan®, also known as Federal Employee Program®, FEP®, would like to share information in regards to the turnaround time needed from the provider for urgent/non-urgent precertification requirements.

The Anthem FEP turnaround time for urgent/non-urgent precertification requirements follow the National Committee for Quality Standards (NCQA) and are outlined below:

- Urgent Concurrent - 24 hours (1 day)
- Urgent Preservice - 72 hours (3 days)
- Non-Urgent Preservice - 15 calendar days
- Post-service - 30 calendar days

In addition, Anthem FEP offers an Advanced Benefit Determination (ABD) for elective services.

- ABD - 15 calendar days

This service is offered as a courtesy and follows NCQA standards, if you would like more information regarding the ABD review process, please contact FEP Utilization Management at the number below.

For additional questions, please contact us at Anthem FEP Utilization Management: 800-860-2156 (8am - 7pm ET) Monday - Friday.

URL: <https://providernews.anthem.com/nevada/article/pre-certification-request-turnaround-times-for-the-federal-employee-program>

US Antibiotic Awareness Week is November 11-18, 2019

Published: Oct 1, 2019 - **State & Federal** / Federal Employee Plan (FEP)

This is a one week observance that gives organizations and providers an opportunity to raise awareness on the appropriate use of antibiotics and reduce the threat of antibiotic resistance. The Centers for Disease Control and Preventions (CDC) has many tools for providers at <https://www.cdc.gov/antibiotic-use/week/toolkit.html>. Posters, prescriptions pads, social media posts, patient education pieces, sticker and counter clings, and more can be found on the CDC website.

During U.S. Antibiotic Awareness Week and throughout the year, the CDC promotes *Be Antibiotics Aware*, an educational effort to raise awareness about the importance of safe antibiotic prescribing and use.

Be Antibiotics Aware has resources to help healthcare professionals (in outpatient and inpatient settings) educate patients and families about antibiotic use and risks for potential side effects. For more information visit: https://www.cdc.gov/antibiotic-use/?s_cid=NCEZID-AntibioticUse-005.

URL: <https://providernews.anthem.com/nevada/article/us-antibiotic-awareness-week-is-november-11-18-2019-2>

Medical Policies and Clinical Utilization Management Guidelines update

Published: Oct 1, 2019 - **State & Federal** / Medicare

Category: Medicare

The *Medical Policies* and *Clinical Utilization Management (UM) Guidelines* below were developed or revised to support clinical coding edits. Several policies and guidelines were revised to provide clarification only and are not included. Existing precertification requirements have not changed. **Please note:** The *Medical Policies* and *Clinical UM Guidelines* below are followed in the absence of Medicare guidance.

Please share this notice with other members of your practice and office staff.

To view a guideline, visit the provider website at www.anthem.com/medicareprovider.

Notes/updates

Updates marked with an asterisk (*) denote that the criteria may be perceived as more restrictive:

- * DME.00037 — added devices that combine cooling and vibration to the investigational and not medically necessary statement
- * LAB.00027 — added Mediator Release Test to investigational and not medically necessary statement
- * LAB.00033 — clarified investigational and not medically necessary statement to include 4Kscore and AR-V7
- * OR-PR.00003:

- Clarified medically necessary position statement criteria 2 through 4
- Added statement that use of prosthetic devices that combine both a microprocessor controlled knee and foot-ankle prosthesis is considered investigational and not medically necessary for all indications
- * SURG.00011:
 - Added new medically necessary and investigational and not medically necessary statements addressing amniotic membrane-derived products for conjunctival and corneal indications, including KeraSys and Prokera
 - Added new products to investigational and not medically necessary statement
- * SURG.00045:
 - Added erectile dysfunction, Peyronie’s disease and wound repair to the investigational and not medically necessary statement
 - Revised title
- * SURG.00121 — added investigational and not medically necessary statement to address use of transcatheter tricuspid valve repair or replacement for all indications
- The following AIM Specialty Health® updates took effect on September 28, 2019:
 - Advanced imaging:
 - Imaging of the heart
 - Oncologic imaging
 - Vascular imaging
 - Proton beam therapy
 - Rehabilitative therapies — physical therapy, occupational therapy and speech therapy (new)

Medical Policies

On June 6, 2019, the Medical Policy and Technology Assessment Committee (MPTAC) approved the following *Medical Policies* applicable to Anthem Blue Cross and Blue Shield

(Anthem).

Publish date	Medical Policy #	Medical Policy title	New or revised
June 13, 2019	MED.00129	Gene Therapy for Spinal Muscular Atrophy	New
June 13, 2019	GENE.00029	Genetic Testing for Breast and/or Ovarian Cancer Syndrome	Revised
June 13, 2019	* SURG.00011	Allogeneic, Xenographic, Synthetic, and Composite Products for Wound Healing and Soft Tissue Grafting	Revised
June 13, 2019	SURG.00023	Breast Procedures; including Reconstructive Surgery, Implants and Other Breast Procedures	Revised
June 13, 2019	SURG.00028	Surgical and Minimally Invasive Treatments for Benign Prostatic Hyperplasia (BPH) and Other Genitourinary Conditions	Revised
June 27, 2019	GENE.00025	Molecular Profiling and Proteogenomic Testing for the Evaluation of Malignancies Previous title: Molecular Profiling and Proteogenomic Testing for the Evaluation of Malignant Tumors	Revised
June 27, 2019	DRUG.00046	Ipilimumab (Yervoy®)	Revised
June 27, 2019	DRUG.00053	Carfilzomib (Kyprolis®)	Revised
June 27, 2019	DRUG.00062	Obinutuzumab (Gazyva®)	Revised
June 27, 2019	DRUG.00067	Ramucirumab (Cyramza®)	Revised
June 27, 2019	DRUG.00071	Pembrolizumab (Keytruda®)	Revised
June 27, 2019	DRUG.00075	Nivolumab (Opdivo®)	Revised
June 27, 2019	DRUG.00107	Avelumab (Bavencio®)	Revised
June 27, 2019	GENE.00044	Analysis of PIK3CA Status in Tumor Cells	Revised

June 27, 2019	* SURG.00121	Transcatheter Heart Valve Procedures	Revised
June 27, 2019	GENE.00001	Genetic Testing for Cancer Susceptibility	Revised
June 27, 2019	GENE.00043	Genetic Testing of an Individual's Genome for Inherited Diseases	Revised
June 27, 2019	LAB.00011	Analysis of Proteomic Patterns	Revised
June 27, 2019	LAB.00015	Detection of Circulating Tumor Cells in the Blood as a Prognostic Factor for Cancer	Revised
July 10, 2019	GENE.00051	Bronchial Gene Expression Classification for the Diagnostic Evaluation of Lung Cancer	New
July 10, 2019	SURG.00153	Cardiac Contractility Modulation Therapy	New
July 10, 2019	* DME.00037	Cooling Devices and Combined Cooling/Heating Devices	Revised
July 10, 2019	DME.00038	Static Progressive Stretch (SPS) and Patient-Actuated Serial Stretch (PASS) Devices	Revised
July 10, 2019	GENE.00011	Gene Expression Profiling for Managing Breast Cancer Treatment	Revised
July 10, 2019	* LAB.00027	Selected Blood, Serum and Cellular Allergy and Toxicity Tests	Revised
July 10, 2019	* LAB.00033	Protein Biomarkers for the Screening, Detection and Management of Prostate Cancer	Revised
July 10, 2019	MED.00109	Corneal Collagen Cross-Linking	Revised
July 10, 2019	* OR- PR.00003	Microprocessor Controlled Lower Limb Prosthesis	Revised
July 10, 2019	SURG.00005	Partial Left Ventriculectomy	Revised
July 10, 2019	* SURG.00045	Extracorporeal Shock Wave Therapy Previous Title: Extracorporeal Shock Wave Therapy for Orthopedic Conditions	Revised
July 10, 2019	SURG.00120	Internal Rib Fixation Systems	Revised
September 4, 2019	GENE.00010	Genotype Panel Testing for Genetic Polymorphisms to Determine Drug-Metabolizer Status Previous title: Genotype	

Clinical UM Guidelines

On June 6, 2019, the MPTAC approved the following *Clinical UM Guidelines* applicable to Anthem. These guidelines were adopted by the Medical Operations Committee for Medicare Advantage members on July 5, 2019.

Publish date	Clinical UM Guideline #	Clinical UM Guideline title	New or revised
June 27, 2019	CG-SURG-97	Cardioverter Defibrillators	New
June 27, 2019	CG-DRUG-98	Bendamustine Hydrochloride	Revised
June 27, 2019	CG-LAB-09	Drug Testing or Screening in the Context of Substance Use Disorder and Chronic Pain	Revised
June 27, 2019	CG-LAB-14	Respiratory Viral Panel Testing in the Outpatient Setting	Revised
July 10, 2019	CG-SURG-100	Laser Trabeculoplasty and Laser Peripheral Iridotomy	New
July 10, 2019	CG-ADMIN-01	Clinical Utilization Management (UM) Guideline for Pre-Payment Review Medical Necessity Determinations When No Other Clinical UM Guideline Exists	Revised
July 10, 2019	CG-ANC-06	Ambulance Services: Ground; Non-Emergent	Revised
July 10, 2019	CG-DME-03	Neuromuscular Stimulation in the Treatment of Muscle Atrophy	Revised
July 10, 2019	CG-DME-07	Augmentative and Alternative Communication (AAC) Devices with Digitized or Synthesized Speech Output Previous title: Augmentative and Alternative Communication (AAC) Devices/Speech Generating Devices (SGD)	Revised
July 10, 2019	CG-DME-08	Infant Home Apnea Monitors	Revised
July 10, 2019	CG-DME-39	Dynamic Low-Load Prolonged-Duration Stretch Devices	Revised
July 10, 2019	CG-DME-42	Non-implantable Insulin Infusion and Blood	

Glucose Monitoring Devices	Revised		
July 10, 2019	CG-DME-45	Ultrasound Bone Growth Stimulation	Revised
July 10, 2019	CG-MED-41	Moderate to Deep Anesthesia Services for Dental Surgery in the Facility Setting	Revised
July 10, 2019	CG-MED-49	Auditory Brainstem Responses (ABRs) and Evoked Otoacoustic Emissions (OAEs) for Hearing Disorders	Revised
July 10, 2019	CG-MED-57	Cardiac Stress Testing with Electrocardiogram	Revised
July 10, 2019	CG-MED-59	Upper Gastrointestinal Endoscopy in Adults	Revised
July 10, 2019	CG-SURG-11	Surgical Treatment for Dupuytren's Contracture	Revised
July 10, 2019	CG-SURG-17	Trigger Point Injections	Revised
July 10, 2019	CG-SURG-35	Intracytoplasmic Sperm Injection (ICSI)	Revised
July 10, 2019	CG-SURG-49	Endovascular Techniques (Percutaneous or Open Exposure) for Arterial Revascularization of the Lower Extremities	Revised
July 10, 2019	CG-SURG-81	Cochlear Implants and Auditory Brainstem Implants	Revised
July 10, 2019	CG-SURG-85	Hip Resurfacing	Revised
July 10, 2019	CG-SURG-93	Angiographic Evaluation and Endovascular Intervention for Dialysis Access Circuit Dysfunction	Revised
September 4, 2019	CG-GENE-11	Genotype Testing for Individual Genetic Polymorphisms to Determine Drug-Metabolizer Status	New
September 4, 2019	CG-GENE-		

10	Chromosomal Microarray Analysis (CMA) for Developmental Delay, Autism Spectrum Disorder, Intellectual Disability (Intellectual Developmental Disorder) and Congenital Anomalies	New	
September 4, 2019	CG-SURG-101	Ablative Techniques as a Treatment for Barrett's Esophagus	New
September 4, 2019	CG-SURG-102	Alcohol Septal Ablation for Treatment of Hypertrophic Cardiomyopathy	New

ABSCRNU-0061-19 August 2019

503273MUPENMUB

URL: <https://providernews.anthem.com/nevada/article/medical-policies-and-clinical-utilization-management-guidelines-update-15>

Update: 2019 risk adjustment provider trainings

Published: Oct 1, 2019 - **State & Federal** / Medicare

Category: Medicare

The Medicare Risk Adjustment Regulatory Compliance team at Anthem Blue Cross and Blue Shield offers two provider training programs regarding Medicare risk adjustment guidelines. Information for each training is outlined below. The Medicare Risk Adjustment Regulatory Compliance team developed the following two provider trainings. This update outlines the training series:

Medicare risk adjustment and documentation guidance (general)

When – offered the first Wednesday of each month from December 5, 2018, to November 6, 2019 at 1 to 2 p.m. Eastern time.

Learning objective – This training will provide an overview of Medicare Risk Adjustment, including the Risk Adjustment Factor and the Hierarchical Condition Category (HCC) Model,

with guidance on medical record documentation and coding.

Credit – This activity has been reviewed and is acceptable for up to one prescribed credit by the American Academy of Family Physicians.

If you are interested in joining us to learn how providers play a critical role in facilitating the risk adjustment process, register for one of the monthly training sessions at the link below: <https://antheminc.adobeconnect.com/admin/show-event-catalog?folder-id=38826374>.

Medicare risk adjustment, documentation and coding guidance (condition specific)

When – offered on the fourth Wednesday of every other month from January 23, 2019 to November 27, 2019 from noon to 1 p.m. Eastern time.

Learning objective – This is a collaborative learning event with Enhanced Personal Health Care (EPHC) to provide in-depth disease information pertaining to specific conditions including an overview of their corresponding hierarchical condition categories (HCC), with guidance on documentation and coding.

Credit – This live series activity has been reviewed and is acceptable for credit by the American Academy of Family Physicians.

For those interested in joining us for this six-part training series, please see the list of topics and scheduled training dates below:

Red flag HCCs, part one – *Register for recording of live session.*

Training will cover HCCs most commonly reported in error as identified by CMS: chronic kidney disease (stage 5), ischemic or unspecified stroke, cerebral hemorrhage, aspiration and specified bacterial pneumonias, unstable angina and other acute ischemic heart disease, and end-stage liver disease. Recording will play upon registration.

<https://antheminc.cosocloud.com/e4i5k4h7cf3j/event/registration.html>.

Red Flag HCCs, part two – *Register for recording of live session.*

Training will cover HCCs most commonly reported in error as identified by CMS: atherosclerosis of the extremities with ulceration or gangrene, myasthenia gravis/myoneural disorders and Guillain-Barre syndrome, drug/alcohol psychosis, lung and other severe

cancers, and diabetes with ophthalmologic or unspecified manifestation. Recording will play upon registration.

https://antheminc.cosocloud.com/enfndbyedd5g/event/event_info.html.

Opioids and more: substance abuse and dependence – Recording will play upon registration.

<https://antheminc.cosocloud.com/ekx3tooh22f7/event/registration.html>.

Acute, chronic and status conditions – Recording will play upon registration.

<https://antheminc.cosocloud.com/eeq7am1fht49/event/registration.html>.

Diabetes mellitus and other metabolic disorders – September 25, 2019

<https://antheminc.cosocloud.com/e9l4sxzbd2lq/event/registration.html>.

Behavioral health – November 27, 2019

<https://antheminc.cosocloud.com/eatxsocnqf6h/event/registration.html>.

ABSCRNU-0060-19 August 2019 502690MUPENMUB

URL: <https://providernews.anthem.com/nevada/article/update-2019-risk-adjustment-provider-trainings-2>

Medicare preferred continuous glucose monitors

Published: Oct 1, 2019 - **State & Federal** / Medicare

Category: Medicare

On January 1, 2020, Anthem Blue Cross and Blue Shield (Anthem) will implement a preferred edit on Medicare-eligible continuous glucose monitors (CGMs). Currently, there are two CGM systems covered by CMS under the Medicare Advantage Part D (MAPD) benefit; these are Dexcom and Freestyle Libre. The preferred CGM for Medicare Advantage Part D individual members covered by Anthem will be Freestyle Libre. This edit will only affect

members who are newly receiving a CGM system. Members will need to obtain their CGM system from a retail or mail order pharmacy – not a durable medical equipment (DME) facility. For Dexcom coverage requests, call **1-833-293-0661**.

ABSCRNU-0065-19 August 2019

503236MUPENMUB

URL: <https://providernews.anthem.com/nevada/article/medicare-preferred-continuous-glucose-monitors-4>

Medical drug Clinical Criteria updates

Published: Oct 1, 2019 - **State & Federal** / Medicare

Category: Medicare

On February 22, 2019, and March 14, 2019, the Pharmacy and Therapeutics (P&T) Committee approved changes to *Clinical Criteria* applicable to the **medical drug benefit** for Anthem Blue Cross and Blue Shield. These policies were developed, revised or reviewed to support clinical coding edits.

The *Clinical Criteria* is publicly available on the provider website, and the effective dates will be reflected in the [Clinical Criteria Q1 web posting](#). Visit [Clinical Criteria](#) to search for specific policies.

For questions or additional information, use this [email](#).

ABSCRNU-0050-19 August 2019

502142MUPENMUB

URL: <https://providernews.anthem.com/nevada/article/medical-drug-clinical-criteria-updates-8>

Prior authorization requirements changes effective November 1, 2019

Published: Oct 1, 2019 - **State & Federal** / Medicare

Category: Medicare

Effective **November 1, 2019**, prior authorization (PA) requirements will change for the following services. These services will require PA by Anthem Blue Cross and Blue Shield for Medicare Advantage members. Federal and state law, as well as state contract language and Centers for Medicare & Medicaid Services guidelines (including definitions and specific contract provisions/exclusions) take precedence over these PA rules and must be considered first when determining coverage. **Noncompliance with new requirements may result in denied claims.**

PA requirements will be added to the following codes:

- **0026U** — Oncology (thyroid), DNA and mRNA of 112 genes, next-generation sequencing, fine needle aspirate of thyroid nodule, algorithmic analysis reported as a categorical result
- **0533T** — Continuous recording of movement disorder symptoms, including bradykinesia, dyskinesia, and tremor for 6 days up to 10 days; includes setup, patient training, configuration
- **0534T** — Continuous recording of movement disorder symptoms, including bradykinesia, dyskinesia, and tremor for 6 days up to 10 days; setup, patient training, configuration of monitor
- **0535T** — Continuous recording of movement disorder symptoms, including bradykinesia, dyskinesia, and tremor for 6 days up to 10 days; data upload, analysis and initial report configuration
- **0536T** — Continuous recording of movement disorder symptoms, including bradykinesia, dyskinesia, and tremor for 6 days up to 10 days; download review, interpretation and report
- **0546T** — Radiofrequency spectroscopy, real time, intraoperative margin assessment, at the time of partial mastectomy, with report
- **33270** — Insertion or replacement of permanent subcutaneous implantable defibrillator system, with subcutaneous electrode, including defibrillation threshold evaluation
- **33271** — Insertion of subcutaneous implantable defibrillator electrode
- **77299** — Unlisted procedure, therapeutic radiology clinical treatment planning
- **81205** — BCKDHB (branched-chain keto acid dehydrogenase E1, beta polypeptide) (e.g., Maple syrup urine disease) gene analysis, common variants (e.g., R183P, G278S, E422X)
- **81219** — CALR (calreticulin) (e.g., myeloproliferative disorders), gene analysis, common variants in exon 9

- **81250** — G6PC (glucose-6-phosphatase, catalytic subunit) (e.g., Glycogen storage disease, Type 1a, von Gierke disease) gene analysis, common variants (e.g., R83C, Q347X)
- **81302** — MECP2 (methyl CpG binding protein 2) (e.g., Rett syndrome) gene analysis; full sequence analysis
- **81303** — MECP2 (methyl CpG binding protein 2) (e.g., Rett syndrome) gene analysis; known familial variant
- **81304** — MECP2 (methyl CpG binding protein 2) (e.g., Rett syndrome) gene analysis; duplication/deletion variants
- **81331** — SNRPN/UBE3A (small nuclear ribonucleoprotein polypeptide N and ubiquitin protein ligase E3A) (e.g., Prader-Willi syndrome and/or Angelman syndrome), methylation analysis
- **81332** — SNRPN/UBE3A (small nuclear ribonucleoprotein polypeptide N and ubiquitin protein ligase E3A) (e.g., Prader-Willi syndrome and/or Angelman syndrome), methylation analysis
- **81400** — Molecular pathology procedure, Level 1 (e.g., identification of single germline variant e.g., SNP by techniques such as restriction enzyme digestion or melt curve analysis) ACADM (acyl—CoA dehydrogenase, C-4 to C-12 straight chain, MCAD) (e.g., medium chain acyl dehydrogenase deficiency)
- **81401** — Molecular pathology procedure, Level 2 (e.g., 2-10 SNPs, 1 methylated variant, or 1 somatic variant typically using nonsequencing target variant analysis, or detection of a dynamic mutation disorder/triplet repeat) ABL (c-abl oncogene 1, receptor tyrosine kinase) (e.g., acquired imatinib resistance)
- **81402** — Molecular pathology procedure, Level 3 (e.g., >10 SNPs, 2-10 methylated variants, or 2-10 somatic variants typically using nonsequencing target variant analysis, immunoglobulin and T-cell receptor gene rearrangements, duplication/deletion variants 1 exon) CYP21A2 (cytochrome P450, family 21, subfamily A, polypeptide 2) (e.g., congenital adrenal hyperplasia, 21-hydroxylase deficiency), common variants (e.g., IVS2-13G, P30L, I172N, exon 6 mutation cluster I235N, V236E, M238K)
- **81402** — Molecular pathology procedure, Level 3 (e.g., >10 SNPs, 2-10 methylated variants, or 2-10 somatic variants typically using nonsequencing target variant analysis, immunoglobulin and T-cell receptor gene rearrangements, duplication/deletion variants 1 exon) CYP21A2 (cytochrome P450, family 21, subfamily A, polypeptide 2) (e.g., congenital adrenal hyperplasia, 21-hydroxylase deficiency), common variants (e.g., IVS2-13G, P30L, I172N, exon 6 mutation cluster I235N, V236E, M238K)
- **81407** — Molecular pathology procedure, Level 8 (e.g., analysis of 26-50 exons by DNA sequence analysis, mutation scanning or duplication/deletion variants of >50 exons,

sequence analysis of multiple genes on one platform) SCN1A (sodium channel, voltage-gated, type 1, alpha subunit) (e.g., generalized epilepsy with febrile seizures), full gene sequence

- **81408** — Molecular pathology procedure, Level 9 (e.g., analysis of >50 exons in a single gene by DNA sequence analysis) FBN1 (fibrillin 1) (e.g., Marfan syndrome), full gene sequence NF1 (neurofibromin 1) (e.g., neurofibromatosis, type 1), full gene sequence RYR1 (ryanodine receptor 1, skeletal) (e.g., malignant hyperthermia), full gene sequence VWF (von Willebrand factor) (e.g., von Willebrand disease types 1 and 3), full gene sequence
- **97033** — Application of a modality to 1 or more areas; iontophoresis, each 15 minutes
- **C9042** — Injection, bendamustine hcl (belrapzo), 1 mg
- **C9043** — Injection, levoleucovorin, 1 mg
- **C9141** — Injection, factor viii, (antihemophilic factor, recombinant), pegylated-auci (jivi)
- **D9130** — Temporomandibular Joint Dysfunction – Non-Invasive Physical Therapies
- **D9920** — or management, by report
- **J9999** — Not otherwise classified, antineoplastic drugs
- **S3850** — Genetic testing for sickle cell anemia

To request PA, you may use one of the following methods:

- **Web:** <https://www.Availity.com>
- **Phone:** Call the Provider Services number on the back of the member's ID card for PA requirements.

Not all prior authorization requirements are listed here. Detailed prior authorization requirements are available to contracted providers by accessing the Provider Self-Service Tool at <https://www.Availity.com>. Contracted and noncontracted providers who are unable to access Availity may call the Provider Services number on the back of the member's ID card for PA requirements.

ABSCRNU-0052-19 August 2019

503100MUPENMUB

URL: <https://providernews.anthem.com/nevada/article/prior-authorization-requirements-changes-effective-november-1-2019-6>

MCG Care Guidelines update and customizations

Published: Oct 1, 2019 - **State & Federal** / Medicare

Category: Medicare

The upgrade to the 23rd edition of the MCG Care Guidelines for Anthem Blue Cross and Blue Shield Healthcare Solutions (Anthem) has changed from May 24, 2019, to October 18, 2019. In addition, Anthem has customized some of the MCG Criteria.

Customizations to the 23rd edition of the MCG Care Guidelines:

Effective October 18, 2019, the following customizations will be implemented:

- **Left Atrial Appendage Closure, Percutaneous (W0157)** — customized to refer to SURG.00032 Transcatheter Closure of Patent Foramen Ovale and Left Atrial Appendage for Stroke Prevention
- **Spine, Scoliosis, Posterior Instrumentation, Pediatric (W0156)** — customized to refer to Musculoskeletal Program Clinical Appropriateness Guidelines, Level of Care Guidelines and Preoperative Admission Guidelines

Effective November 1, 2019, customizations will be implanted for Chemotherapy and Inpatient & Surgical Care (W0162) for adult patients. The customizations provide specific criteria and guidance on the following:

- Clinical indications for admission; examples will also be added for:
 - Aggressive hydration needs that cannot be managed in an infusion center.
 - Prolonged marrow suppression.
- Regimens that cannot be managed outpatient; examples will also be added.

Providers can view a summary of the 23rd edition of the MCG Care Guidelines customizations [online](#) by selecting **Customizations to MCG Care Guidelines 23rd Edition (Publish date November 1, 2019)**.

For questions, contact Provider Services at **1-844-396-2330**.

ANV-NU-0071-19 August 2019

URL: <https://providernews.anthem.com/nevada/article/mcg-care-guidelines-update-and-customizations-4>

Keep up with Medicare news

Published: Oct 1, 2019 - **State & Federal** / Medicare

Category: Medicare

Please continue to check [Important Medicare Advantage Updates](#) at anthem.com/medicareprovider for the latest Medicare Advantage information, including:

- [Medical Policies and Clinical Utilization Management Guidelines update](#)
- [Clinical Laboratory Improvement Amendments for Anthem Blue Cross and Blue Shield](#)
- [Lowering health risks with no-cost statins](#)
- [Assisting your patients in managing the Donut Hole](#)
- [Prior authorization requirements for continuous positive airway pressure supplies](#)

URL: <https://providernews.anthem.com/nevada/article/keep-up-with-medicare-news-86>

New pregnancy notification process using the Availity Portal Benefit Look-Up Tool

Published: Oct 1, 2019 - **State & Federal** / Medicaid

Category: Medicaid

Anthem Blue Cross and Blue Shield Healthcare Solutions (Anthem) offers pregnant women several services and benefits through the New Baby, New LifeSM program. Anthem provides education, support, resources and incentives to members throughout the prenatal and

postpartum period. Our goal is to ensure all pregnant members are identified early in their pregnancies so that they can take full advantage of these services.

We are working with Availity, the vendor supporting the Benefit Look-Up Tool you may currently use in your OB office, to get information about newly identified pregnant women. This new process, including the *HEDIS® Maternity Attestation* form, helps connect members to additional benefits as soon as possible using a few simple steps.

How it works

When an Anthem member of childbearing age visits the OB office, the office associate is prompted to ask the question “Is the member pregnant?” during the eligibility and benefits inquiry process. If the response is yes, the system asks about the due date, and a *HEDIS Maternity Attestation* form is generated for the OB office to complete. On this electronic form, providers are asked to provide other relevant information including the date of the first prenatal care visit, delivery date and postpartum visit date.

This new, user-friendly workflow generates timely information that aids members, providers and Anthem in improving birth outcomes with early intervention.

We are working hard to support providers throughout Nevada in receiving necessary training for this new workflow. If you have specific questions regarding the new Availity maternity attestation process, please feel free to reach out to Provider Services at **1-844-396-2330**.

HEDIS is a registered trademark of the National Committee for Quality Assurance (NCQA).

Provider FAQ — Availity Portal Pregnancy Notification and HEDIS Maternity Attestation

ANV-NU-0084-19 August 2019

URL: <https://providernews.anthem.com/nevada/article/new-pregnancy-notification-process-using-the-availity-portal-benefit-look-up-tool-6>

Prior authorization changes

Published: Oct 1, 2019 - **State & Federal** / Medicaid

Effective December 1, 2019, prior authorization (PA) requirements are changing for the codes listed below. The listed codes will require PA by Anthem Blue Cross and Blue Shield Healthcare Solutions for Nevada Medicaid members. Federal and state law, as well as state contract language and Centers for Medicare & Medicaid Services guidelines, including definitions and specific contract provisions/exclusions, take precedence over these PA rules and must be considered first when determining coverage. **Noncompliance with new requirements may result in denied claims.**

PA requirements are being added to the following:

- Lower extremity prosthesis — shank foot system with vertical loading pylon (L5987)
- Gait trainer, pediatric size — anterior support, includes all accessories and components (E8002)
- Wheelchair, pediatric size — tilt-in-space, folding, adjustable, without seating system (E1234)
- Wheelchair, pediatric size — tilt-in-space, rigid, adjustable, without seating system (E1233)
- Transport chair, pediatric size (E1037)
- Multi-positional patient transfer system with integrated seat, operated by care giver (E1035)
- Wheelchair accessory — ventilator tray, gimbaled (E1030)
- Water circulating heat pad with pump (E0217)

To request PA, you may use one of the following methods:

- **Web:** <https://www.availity.com>
- **Fax:** 1-800-964-3627
- **Phone:** 1-844-396-2330

ANV-NU-0066-19 August 2019

URL: <https://providernews.anthem.com/nevada/article/prior-authorization-changes-5>

Prior authorization requirements for hyperbaric oxygen and supervision of hyperbaric oxygen therapy

Published: Oct 1, 2019 - **State & Federal** / Medicaid

Category: Medicaid

Effective October 1, 2019, prior authorization (PA) requirements will change for hyperbaric oxygen and supervision of hyperbaric oxygen therapy to be covered by Anthem Blue Cross and Blue Shield Healthcare Solutions. Federal and state law, as well as state contract language and Centers for Medicare & Medicaid Services guidelines, including definitions and specific contract provisions/exclusions, take precedence over these PA rules and must be considered first when determining coverage. **Noncompliance with new requirements may result in denied claims.**

PA requirements will be added to the following:

- G0277 — Hyperbaric oxygen under pressure, full body chamber, per 30-minute interval
- 99183 — Physician attendance and supervision of hyperbaric oxygen therapy, per session

To request PA, you may use one of the following methods:

- **Web:** <https://www.availity.com>
- **Fax:** 1-800-964-3627
- **Phone:** 1-844-396-2330

Not all PA requirements are listed here. Detailed PA requirements are available to contracted providers by accessing the Precertification Lookup Tool at <https://www.availity.com> via <https://mediproviders.anthem.com/nv>. Contracted and noncontracted providers who are unable to access the Availity Portal can call Provider Services at **1-844-396-2330**.

ANV-NU-0065-19 August 2019

URL: <https://providernews.anthem.com/nevada/article/prior-authorization-requirements-for-hyperbaric-oxygen-and-supervision-of-hyperbaric-oxygen-therapy-2>

MCG Care Guidelines update and customizations

Published: Oct 1, 2019 - **State & Federal** / Medicaid

Category: Medicaid

The upgrade to the 23rd edition of the MCG Care Guidelines for Anthem Blue Cross and Blue Shield Healthcare Solutions (Anthem) has changed from May 24, 2019, to October 18, 2019. In addition, Anthem has customized some of the MCG Criteria.

Customizations to the 23rd edition of the MCG Care Guidelines:

Effective October 18, 2019, the following customizations will be implemented:

- **Left Atrial Appendage Closure, Percutaneous (W0157)** — customized to refer to SURG.00032 Transcatheter Closure of Patent Foramen Ovale and Left Atrial Appendage for Stroke Prevention
- **Spine, Scoliosis, Posterior Instrumentation, Pediatric (W0156)** — customized to refer to Musculoskeletal Program Clinical Appropriateness Guidelines, Level of Care Guidelines and Preoperative Admission Guidelines

Effective November 1, 2019, customizations will be implanted for Chemotherapy and Inpatient & Surgical Care (W0162) for adult patients. The customizations provide specific criteria and guidance on the following:

- Clinical indications for admission; examples will also be added for:
 - o Aggressive hydration needs that cannot be managed in an infusion center.
 - o Prolonged marrow suppression.
- Regimens that cannot be managed outpatient; examples will also be added.

Providers can view a summary of the 23rd edition of the MCG Care Guidelines customizations [online](#) by selecting **Customizations to MCG Care Guidelines 23rd Edition (Publish date November 1, 2019)**.

For questions, contact Provider Services at **1-844-396-2330**.

ANV-NU-0071-19 August 2019

URL: <https://providernews.anthem.com/nevada/article/mcg-care-guidelines-update-and-customizations-5>

Keep up with Medicaid news

Published: Oct 1, 2019 - **State & Federal** / Medicaid

Category: Medicaid

Please continue to check [Medicaid Provider Communications & Updates](#) at anthem.com/mediproviders for the latest Medicaid information, including:

- [Medical Policies and Clinical Utilization Management Guidelines update](#)

URL: <https://providernews.anthem.com/nevada/article/keep-up-with-medicaid-news-9>

Pharmacy information available on anthem.com

Published: Oct 1, 2019 - **Products & Programs** / Pharmacy

For more information on copayment/coinsurance requirements and their applicable drug classes, drug lists and changes, prior authorization criteria, procedures for generic substitution, therapeutic interchange, step therapy or other management methods subject to prescribing decisions, and any other requirements, restrictions, or limitations that apply to using certain drugs, visit anthem.com/pharmacyinformation. The commercial drug list is posted to the web site quarterly (the first of the month for January, April, July and October).

FEP Pharmacy updates and other pharmacy related information may be accessed at www.fepblue.org Pharmacy Benefits.

